Additionally, the utilization of AZD6738 (50 nM), an ATR pathway inhibitor, partially inhibits USP47 knockdown-induced suppression of cell viability in CML cells (Supplementary Fig. 6g). Here, ATR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.